NFKB1 and neoplasm: During tumor progression, Ezh2 inhibition amplified vulnerabilities associated with acute inflammatory transcription as revealed by sensitivity of treated tumor cells to inhibition of the cellular machineries involved in proteostasis and RNA synthesis and, indirectly, of the NF-κB pathway.